Trump won’t force Medicaid to cover GLP-1s for obesity. A few states are doing it anyway.

Obesity is a prevalent health issue that affects millions of individuals across the country. For many, traditional methods of weight loss such as diet and exercise may not always be effective. In recent years, a new class of drugs called GLP-1s has offered hope to those struggling with obesity by providing an alternative treatment option.

One individual who has benefited from these drugs is Page Campbell, a 40-year-old single mother of two from Charleston, South Carolina. After her doctor recommended the injectable prescription drug Wegovy as a weight loss aid before bariatric surgery, Campbell eagerly agreed to give it a try. Despite not using a scale at home, Campbell was confident in her efforts to lose weight through lifestyle changes, including improved eating habits and regular exercise.

Wegovy, along with other GLP-1 drugs, has shown promise in helping patients achieve weight loss. However, access to these medications remains limited due to their high cost. While South Carolina’s Medicaid program recently decided to cover GLP-1s for obesity treatment, many other states and private insurers still deem these drugs too expensive for coverage.

The stringent prerequisites for accessing GLP-1 drugs under Medicaid, such as documenting previous weight loss attempts and committing to increased exercise activity, pose additional challenges for patients seeking this treatment. Despite the potential benefits of these drugs, the high cost and rigorous approval process may deter many individuals from pursuing this option.

In response to the rising costs of GLP-1 drugs, manufacturers like Novo Nordisk have begun to lower prices to make them more affordable. However, the long-term expense of these medications, which may need to be taken indefinitely to maintain weight loss, remains a significant barrier for many patients.

While there is ongoing debate about the coverage of GLP-1 drugs under Medicare and Medicaid, public health experts have praised South Carolina Medicaid’s decision to include these medications in its coverage. Still, more work is needed to address the obesity epidemic in the state, as the majority of adults in South Carolina are classified as obese.

In conclusion, while GLP-1 drugs offer a promising treatment option for obesity, challenges such as cost and access limitations continue to hinder their widespread use. As efforts to address obesity continue, a comprehensive approach that combines medication, lifestyle changes, and other interventions may be necessary to effectively combat this complex health issue.